

12. SCHEDULE OF PROCEDURES	12-1
12.1 Eligibility Screening and Baseline Measurements	12-1
12.2 Outcomes, Safety Testing, and Measures for Adherence	12-2
12.2.1 Changes due to early termination of the masked treatment phase	12-5

12. SCHEDULE OF PROCEDURES

12.1 Eligibility Screening and Baseline Measurements

STEP	TEST OR PROCEDURE	COMMENTS
1 - Initial screen	Informed consent #1	
	Screening Glucose	Random and/or fasting fingerstick capillary glucose, read locally
	Screening Questionnaire	Initial review of eligibility criteria
	Height, Weight, Blood pressure	Initial screening for eligibility
2 - OGTT	Informed Consent #2	
	75 gram oral glucose tolerance test (OGTT)	Fingerstick capillary glucose at 0, 120 minute, read locally to determine if subject is eligible 0, 30, 120 minute samples for glucose 0, 30 minute insulin, 0 minute proinsulin
	electrolytes*, TSH*, triglyceride*, serum creatinine, ALT/AST, urine dipstick for protein*, CBC	Laboratory eligibility criteria CBC and urine dipstick for protein
	Medical history & physical	Eligibility evaluation
3 - Run-in start	Informed Consent #3	
	Medical history/physical examination, medications	Baseline evaluation
	Creatinine Clearance	Only for participants who are or will become 80 years of age during the DPP.
	ECG	Read locally for safety, sent to ECG reading center for later reading if eligible
	Nutrient and physical activity questionnaires	
	Placebo dispensed and Diet and physical activity diaries	Initiate run-in
3 - Run-in end	Pill counting, diary evaluation, and Behavioral questionnaires	Run-in evaluation
4 - Baseline/ Randomization	Informed consent #4	
	Derived lipid profile, full beta-quant, ICA, GAD, HbA _{1c} , urine albumin, urine creatinine, fibrinogen, TPA, DNA storage, long term storage, LDL particle size, LDL-ApoB, LDL-cholesterol, HCG*, CRP, and carotid ultrasound	Baseline evaluations, not used for eligibility Full Beta Quant should be done only if TG > 400 mg/dL. HCG determined locally before randomization Carotid ultrasound to be done before randomization.

* laboratory specimens collected at baseline for eligibility

12.2 Outcomes, Safety Testing, and Measures for Adherence

	Time Req. (min.)	Baseline and End of Study	Month												Primary Outcome +
			03	06	12	18	24	30	36	42	48	54	60	66	
Glycemia															
Fasting Glucose		X		X	X	X	X	X	X	X	X	X	X	X	M
30', 120' Glucose	120	X			X		X		X		X		X		M
HbA _{1c}		X		X	X		X		X		X		X		M
Insulin Secretion and Sensitivity															
Fasting, 30' Insulin		X			X		X		X		X		X		M
Fasting Proinsulin		X			X		X		X		X		X		M
Fibrinolysis and Clotting Factors															
Fibrinogen, TPA		X			X										
CRP		X		X	X										
Lipids (Fasting)															
Derived Beta Quant		X		X	X		X		X		X		X		
Full Beta Quant (If ↑ TG)		X		X	X		X		X		X		X		
LDL Particle Size		X		X	X		X		X		X		X		
LDL - ApoB		X		X	X		X		X		X		X		
LDL - CH		X		X	X		X		X		X		X		
Serologic IDDM Evidence															
ICA & GAD Antibodies		X													X
Kidney Function															
Urine Albumin & Creatinine Concentration	5	X													X
Saved Specimens															
		X		X	X		X		X		X		X		

	Time Req. (min.)	Baseline and End of Study	Month												Primary Outcome +
			03	06	12	18	24	30	36	42	48	54	60	66	
Physical															
Height	5	X													
Weight	5	X		X	X	X	X	X	X	X	X	X	X	X	X
Waist/Hip Circumf.	10	X			X		X		X		X		X		
Sagittal Diameter.	5	X			X										
Skin-fold	10	X			X										
Blood Pressure															
Arm BP	10	X		X	X	X	X	X	X	X	X	X	X	X	X
ABI	20	X			X				X						
Quality of Life															
Beck Anxiety & Depression Inventories	10	X			X		X		X		X		X		
MOS SF-36	10	X			X		X		X		X		X		
Quality of Well-Being Scale	10 - 15	X			X		X		X		X		X		
Adherence Measures															
Retention & Treatment Monitoring	20	X		X		X		X		X		X		X	
DPP-Specific Social Support	5	X			X		X		X		X		X		
Medication Adherence Interview*♦	15	X	X	X	X	X	X	X	X	X	X	X	X	X	
Physical Activity & Nutrition															
Modifiable Activity Questionnaire	10	X			X		X		X		X		X		
Low Level Physical Activity Recall	10	X		X	X		X		X		X		X		
Nutrient Intake	25	X			X										
Cardiovascular															
ECG	15	X			X		X		X		X		X		
Symptom History	10	X			X		X		X		X		X		
Carotid Ultrasound	45	X													

	Time Req. (min.)	Baseline and End of Study	Month												Primary Outcome +
			03	06	12	18	24	30	36	42	48	54	60	66	
Other Outcomes															
Interval History Questionnaire	15	X			X		X		X		X		X		
Safety Testing															
CBC (hemoglobin, hematocrit, platelets)*		X		X	X		X		X		X		X		
Blood Chemistries**		X	X	X	X	X	X	X	X	X	X	X	X	X	
Adverse Event Report***		X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pregnancy #															

+ For the Primary Outcome Visit, items marked M need to be collected only if fasting plasma glucoses (i.e., no OGTTs) were collected to determine diabetes.

* In the pharmacological treatment groups.

◆ The Medication Adherence Interview will be completed at the month 1 visit and then at Standard (Form F01) and Major (Form F02) follow-up visits.

** In the pharmacological treatment groups, for liver function, liver enzymes (ALT-SGPT, AST-SGOT) and for kidney function, serum creatinine will be collected every 6 months. In addition, liver enzymes will be collected at the month 3 visit.

*** Adverse events will be collected at Standard (Form F01), Major (Form F02), and Interim (F03) follow-up visits.

Pregnancy tests as needed based on symptoms and menstrual history.

Note: CBC and pregnancy tests are local measures.

12.2.1 Changes due to early termination of the masked treatment phase

Data will be collected as specified in protocol version 4.2 with the following modifications.

- a. Scheduled “End of study visits” (as noted in Table 12.2) will not be conducted due to early termination of DPP.
- b. A urine specimen to measure urine albumin and creatinine concentration will be collected.
- c. Carotid ultrasound may be conducted at a visit to be scheduled.
- d. Questions concerning urinary incontinence (Q13), and questions concerning barriers, support and medication assignment (Q14) in the DPP will be asked.